La Jolla Pharmaceutical Company announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests. A search for a new Chief Executive Officer has been initiated. In the interim, a committee of the Board, comprised of Kevin Tang and Craig Johnson, will provide Board-level oversight of the Company's management team.
La Jolla Pharmaceutical Company
Equities
LJPC
US5034596040
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+20.29% | 127B | |
+24.27% | 117B | |
+25.44% | 27.67B | |
-18.57% | 20.33B | |
-15.17% | 16.79B | |
-16.49% | 15.63B | |
+12.97% | 14.84B | |
-47.10% | 14.65B | |
+57.08% | 14.43B |